T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma ...Middle East

BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial for the treatment of recurrent...

Hence then, the article about t maximum pharmaceutical s allogeneic car t therapy mt027 receives fda ind clearance to proceed to phase ii clinical trial for recurrent glioblastoma was published today ( Sunday 21/12/2025 - 03:24 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma )

Also on site :

• 2026 IMS .. IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206
• The Terrifying 1975 Urban Legend: Did the Ohio Players Record a Real Murder Scream on No.1 Hit ‘Love Rollercoaster’
• The Trump administration said it would prioritize ending mother-to-child HIV transmission. Health workers say it cut services